Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships G42 Healthcare Research Technology Projects LLC (collaboration and license; joint development and commercialization of cadisegliatin in the Middle East, Africa and Central Asia; single-digit royalties); Novo Nordisk (worldwide exclusive license to GKA program; milestones plus mid-single-digit royalties)
Indications
Type 1 diabetes, adjunctive to insulin(Phase 3)
Type 2 diabetes (insulin-using patients)(Phase 2)
Catalysts
— third quarter of 2026
— late 2026
Status note Liver-selective glucokinase activator. FDA granted Breakthrough Therapy designation in 2021 for T1D adjunctive-to-insulin use. Phase 3 CATT1 trial resumed May 2025. Phase 2 trial in insulin-using T2D patients in the Middle East initiated December 2025 with G42. Additional registrational studies for T1D expected to start in 2027.
HPP737
Stage not disclosed · ActiveModality: small molecule (oral)
Target PDE4
Partnerships Newsoara Biopharma Co., Ltd. (exclusive global license, Second Amendment January 2026; $20M upfront received February 2026; up to ~$50M development milestones, $65M sales milestones, mid-single-digit royalties)
Indications
Not disclosed(Stage not disclosed)
Status note Development and commercialization handled by Newsoara under expanded global rights (Second Amendment, January 2026; upfront fee received February 2026).
azeliragon
Stage not disclosed · ActiveModality: small molecule (oral)
Target RAGE (receptor for advanced glycation end-products)
Partnerships Cantex Pharmaceuticals, Inc. (exclusive worldwide license, June 2021; Cantex responsible for development and commercialization; tiered downstream profit arrangement)
Indications
Not disclosed(Stage not disclosed)
Status note Cantex holds exclusive worldwide rights to develop and commercialize azeliragon, vTv's novel RAGE antagonist.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.